174641-44-2
174641-44-2
Chemical Structure
HEP-1
Synonym(s): Human ezrin peptide (324-337)
- No. CAS: 174641-44-2
- Formula:C74H132N26O27
- Molecular Weight:1818.00
InChIKey: HTQONPPEZULJKY-XRBNWYQFSA-N
SMILES: O=C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(O)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](C(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCC(O)=O)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H]([C@H](O)C)N
Biological Activity: HEP-1 (Human ezrin peptide (324 - 337)) is an orally active peptide with antiviral, anti-inflammatory, and immunomodulatory activities. HEP-1 is effective against infections by various viruses such as HIV, HCV, herpes viruses, HPV, and influenza viruses. As an immunomodulator, HEP-1 can enhance the adaptive immunity mediated by B cells and T cells. HEP-1 can also increase the antibody titers after hepatitis B vaccination. HEP-1 can be used in the research of viral infections and inflammation-related diseases[1][2].
| Referencia número | Nombre del producto | Pureza | Descripciòn | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
HEP-1 | 99.88% | HEP-1 (Human ezrin peptide (324 - 337)) is an orally active peptide with antiviral, anti-inflammatory, and immunomodulatory activities. HEP-1 is effective against infections by various viruses such as HIV, HCV, herpes viruses, HPV, and influenza viruses. As an immunomodulator, HEP-1 can enhance the adaptive immunity mediated by B cells and T cells. HEP-1 can also increase the antibody titers after hepatitis B vaccination. HEP-1 can be used in the research of viral infections and inflammation-related diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Autocamtide 2 | 98.94% | Autocamtide 2 is a highly selective peptide substrate of calcium/calmodulin-dependent protein kinase II (CaMKII). It can be used in the CaMKII activity assay. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SAP15 | SAP15 (Synthetic anti-inflammatory peptide 15) is a synthetic anti-inflammatory peptide consisting of 15 amino acids designed from human beta-defensin 3. SAP15 has the ability to penetrate cells and is able to induce downregulation of intracellular inflammation. SAP15 inhibits inflammation by inhibiting the phosphorylation of HDAC5 and thereby reducing the phosphorylation of NF-κB p65. SAP15 inhibits HDAC5 and NF-κB p65 phosphorylation in LPS (HY-D1056)-induced macrophages. SAP15 increases the expression of aggrecan and type II collagen and decreases the expression of osteocalcin in LPS-induced chondrocytes. SAP15 can be used in the study of inflammation regulation and anti-inflammatory therapy of biomaterials. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ALFA-tag | 99.40% | ALFA-tag is an α-helical peptide epitope tag. ALFA-tag is recognized by the high-affinity Nb-ALFA nanobody (Kd = 26 pM). The ALFA system, composed of ALFA-tag and ALFA-Nb, is widely adopted and applied in various fields such as immunofluorescence, super-resolution microscopy, immunoblotting, and protein purification. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ccβ | ccβ is a 17-residue peptide that folds into a coiled-coil trimer at low temperatures and aggregates to form amyloid fibrils at high temperatures. ccβ serves as a simple model system for investigating α-helix to β-sheet conformational transitions and template-mediated aggregation processes associated with prion and amyloidogenic diseases. ccβ can be used in studies of prion diseases and Alzheimer's disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
NLS-CPP | NLS-CPP is a nuclear localization signal (NLS)-cell-penetrating peptide, which contains the NLS of OCT6. NLS-CPP facilitates nuclear delivery. NLS-CPP can be used for chronic inflammatory diseases s research, such as metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
RESA peptide | 99.97% | RESA peptide is a substrate peptide of β-adrenergic receptor kinase (βARK). RESA peptide serves as a substrate for βARK-mediated phosphorylation, and its N-terminal acidic residues enhance phosphorylation efficiency and substrate binding capacity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Casein Kinase II Receptor Peptide | Casein Kinase II Receptor Peptide is a substrate for casein kinase II with an Km value of 500 µM. Casein Kinase II Substrate can be used for measure casein kinase II activity in crude enzyme preparations. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Casein Kinase II Substrate | 99.93% | Casein Kinase II Substrate is a casein kinase II (CK2) peptide substrate that can be selectively phosphorylated by CK2. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CBP501 Affinity Peptide | CBP501 Affinity Peptide is a Chk kinase inhibitor that can abrogate G2 arrest induced by DNA-damaging agents. CBP501 Affinity Peptide can be used in cancer research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CHRG01 | CHRG01 is a biological active peptide. (CHRG01 is derived from human b-defensin 3 (hBD3) C-terminal amino acids 54 to 67, with all Cys residues substituted with Ser. This substitution removes all disulfide bond linkages within the sequence. CHRG01, like hBD3, displays electrostatic-dependent antimicrobial properties.) | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Chulkina MM, et al. Pharmaceutical grade synthetic peptide Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu ameliorates DSS-induced murine colitis by reducing the number and pro-inflammatory activity of colon tissue-infiltrating Ly6G+ granulocytes and Ly6C+ monocytes. Peptides. 2020 Oct;132:170364. [Content Brief]
- [2]. Holms RD, et al. Ezrin Peptide Therapy from HIV to COVID: Inhibition of Inflammation and Amplification of Adaptive Anti-Viral Immunity. Int J Mol Sci. 2021 Oct 28;22(21):11688. [Content Brief]
